Ortho-nitrobenzaldehyde (2-nitrobenzaldehyde, CAS 552-89-6) is a pharma-grade aromatic nitro aldehyde intermediate supplied for API synthesis routes that terminate in tablet, capsule, granule, oral liquid, and injectable dosage forms. The substance is not a final drug product or a conventional formulated API; it functions as a carbonyl electrophile in heterocyclic condensations, particularly in dihydropyridine calcium-channel-modulator synthesis, where the ortho nitro group controls ring-closure regiochemistry. The product model is specification-defined rather than a single commercial brand. A typical line identifier encodes the application route—O for oral, I for injectable, G for granulation—followed by the residual solvent class and milled particle size code; however, nomenclature is manufacturer-specific. Purchasing control therefore relies on the certificate of analysis, the supplier’s active pharmaceutical ingredient intermediate registration dossier, and the downstream marketing authorization holder’s approved vendor qualification, not on a generic model number.

What Pharmacopoeial Limits Distinguish Oral Grade from Injectable Grade Material?

For both oral and injectable routes, the acceptance envelope includes assay (anhydrous) 98.0–102.0% w/w, chromatographic purity ≥ 99.0% by area, melting range 42.0–44.0 °C, loss on drying ≤ 0.5% w/w, and residue on ignition ≤ 0.1% w/w. Injectable-grade material is controlled for bacterial endotoxins per USP <85> or Ph. Eur. 2.6.14 only when the final API is intended for parenteral administration and the intermediate is used after the last purification step. Residual solvent limits follow ICH Q3C options; Class 2 solvents are controlled with the same limits as the final drug substance because downstream recrystallization cannot be assumed to remove all solvents if the intermediate is isolated from the same solvent system. Elemental impurities are assessed according to ICH Q3D Option 1, with nickel and palladium as risk elements when catalytic reduction follows aldehyde condensation.

No harmonized pharmacopoeial monograph exists specifically for ortho-nitrobenzaldehyde as an intermediate; the limits above are typical supplier specifications and are not compendial acceptance criteria unless the final drug substance monograph incorporates them. Residual solvent control is route-dependent because the synthesis of ortho-nitrobenzaldehyde typically uses toluene, acetic acid, or ethyl acetate, and these solvents can appear in the final intermediate if drying is incomplete. Headspace gas chromatography with flame ionization detection per USP <467> is used with a capillary column; Class 2 solvents such as toluene are controlled below 890 ppm when the material is declared as injectable-grade and below 5000 ppm for oral-grade depending on the final API solvent index. The most common residual solvent carryover is acetic acid from the oxidation step; its concentration in the wet cake is reduced by vacuum drying at no more than 35.0 °C, and a limit of ≤ 1000 ppm in the dried material is typical when acetic acid is used.

Older pharmacopoeial heavy metals tests per USP <231> have been replaced by elemental impurity limits per USP <232>/<233>. For this intermediate, the binding control standard is ICH Q3D Option 1, with permitted daily exposure values for lead, cadmium, nickel, and palladium calculated from the final drug substance route. The intermediate specification is therefore not a fixed heavy metals limit but a route-specific elemental impurity target that accounts for downstream reduction catalysts and reactor metallurgy. Injectable-grade material adds a particulate-matter control step because fibrous or insoluble inorganic contamination carried into the final API can affect the sterile filtration of the injectable solution.

On solid-dose compounding lines, the main processing constraint is the low melting range. Ortho-nitrobenzaldehyde softens near 42.0 °C, so high-shear granulation and dry milling must be performed with jacket temperatures below 20.0 °C, and the product should be equilibrated in the processing suite for not less than 4 h when the relative humidity exceeds 60% because surface water absorption increases cohesiveness. Milling through a conical mill with a 0.5 mm screen under a nitrogen blanket reduces D90 to ≤ 75 µm. For low-dose dry blends, the particle size specification D10 ≥ 10 µm, D50 25–45 µm, and D90 ≤ 75 µm is used to match the API particle size distribution and avoid segregation in rotary press feed frames. The Hausner ratio is maintained between 1.15 and 1.35. Published production-scale data for ribbon compaction of this specific intermediate is limited; wet granulation is therefore the preferred dry granulation alternative when the downstream API is not moisture-labile.

Granule, Tablet, Capsule, and Injectable Unit Operation Interfaces

In API manufacturing, ortho-nitrobenzaldehyde is charged as a solid to glass-lined reactors, usually in polar aprotic or alcoholic solvent systems. The compound has a molecular formula C7H5NO3 and a molecular weight of 151.12 g/mol; its solubility in water is low, while it is soluble in ethanol, ethyl acetate, and toluene. For granulation intermediates, the particle size and residual acetic acid content are the main carryover risks. In tablet and capsule formulations, the intermediate itself is not present; instead, the isolated API derived from ortho-nitrobenzaldehyde must comply with blend uniformity per USP <905> and dissolution per USP <711>. For injectable APIs, the intermediate’s elemental impurity contribution is included in the ICH Q3D risk assessment because nickel and palladium catalysts used in nitro reduction steps may introduce residual metals. The sterile filterability of the final injectable is not affected by the intermediate directly, but particulate-matter limits per USP <788> can be compromised if the intermediate carries fibrous or insoluble inorganic contamination; therefore injectable-grade material is filtered through a 0.45 µm membrane before final packaging.

In wet granulation, the intermediate is not typically granulated directly; the API produced from it is granulated with lactose monohydrate, microcrystalline cellulose, and crospovidone. The critical intermediate-related failure mode is residual insoluble material that reduces tablet hardness and increases friability. Batch-to-batch variance in melting range can indicate incomplete drying or isomer contamination; if the melting range broadens above 44.5 °C, para or oxidation impurities should be suspected. For injectable routes, the intermediate is generally consumed before sterile filtration and is not present in the finished solution, but its residual solvent profile still appears in the API supplier questionnaire because it influences the final drug substance’s residual solvent declaration.

When Ortho-Nitrobenzaldehyde Replaces Para or Meta Isomers in a Synthetic Sequence

The substitution pattern determines both the melting point and the reactivity of the aldehyde. Ortho-nitrobenzaldehyde melts at 42.0–44.0 °C, 3-nitrobenzaldehyde at 56.0–58.0 °C, and 4-nitrobenzaldehyde at 103.0–106.0 °C; the low melting range of the ortho isomer is due to intramolecular nitro–aldehyde interactions that disrupt lattice packing. In Hantzsch-type condensations, the ortho nitro group increases the electrophilicity of the aldehyde carbon through both inductive and field effects, but its steric bulk slows nucleophilic attack relative to the para isomer in non-hydrogen-bond-donor solvents. In reduction sequences, ortho-nitrobenzaldehyde can undergo intramolecular cyclization to anthranil derivatives, whereas the para isomer follows a cleaner nitro-to-amine reduction pathway. These differences require route-specific impurity monitoring because the ortho-specific by-products are not shared with meta or para material.

Technical-grade ortho-nitrobenzaldehyde may contain up to 2.0% w/w para isomer and oxidation by-products; pharma-grade material has chromatographic purity ≥ 99.0% and specified isomeric content. The ortho isomer is the only substitution pattern that directs the desired dihydropyridine ring closure in the most common calcium-channel-modulator synthesis. Meta and para isomers produce regioisomeric or unreactive intermediates that must be removed by recrystallization. In addition, pharma-grade material for injectable APIs is tested for endotoxins and is packaged in low-particulate liners, while technical-grade material is not.

Storage and handling boundary conditions are defined by photochemical sensitivity. In solution, ortho-nitrobenzaldehyde is known to undergo intramolecular hydrogen abstraction on exposure to UV-A/UV-B, converting the nitro group to a nitroso species and the aldehyde to a carboxylic acid. This pathway is why amber glass or double polyethylene-lined fiber drums are specified for pharma-grade material, and why the product is stored below 25.0 °C in a dry, light-protected area. In solid form, surface discoloration may occur under extended direct light exposure; the appearance acceptance is off-white to pale yellow crystalline powder, and dark amber discoloration triggers re-testing. For injectable-grade material, any reprocessing after photodegradation is not recommended because nitroso and carboxylic acid by-products are not part of the registered impurity profile.

Thermal and Photochemical Degradation Pathways in Storage and Drying

Thermal exposure above the melting onset is the main stability risk. Because the compound melts at 42.0–44.0 °C, drying must be conducted under vacuum at no more than 35.0 °C, with a target loss on drying ≤ 0.5% w/w. Drum ovens and tray dryers are operated under nitrogen to reduce aldehyde oxidation to the corresponding nitrobenzoic acid. For injectable-grade material, an additional forced-air cooling step is avoided after drying because condensation can increase water content unevenly across the batch. In-process monitoring by Raman spectroscopy is not yet routine; most sites rely on melting range and HPLC purity after drying. When the product is milled after drying, the mill chamber is maintained at 15.0–20.0 °C to prevent heat-induced caking on the screen. Supplier technical bulletins generally recommend shallow static-bed depth and avoid deep-bed tray drying because the low melting range creates a temperature gradient that can fuse particles at the bottom of the bed.

Analytical control includes residual ortho-nitrobenzaldehyde content in the final API by HPLC with UV detection at 254 nm; the limit is usually not more than 0.10% w/w in the isolated API. Degradation products such as 2-nitrosobenzoic acid and 2-nitrobenzoic acid are resolved using a C18 column under acidic mobile phase. Residual water is determined by Karl Fischer titration per USP <921> Method Ia; a typical limit is ≤ 0.5% w/w. The product is not compatible with strong alkali or primary amine storage conditions because the aldehyde forms imines and the nitro group can be reduced under catalytic hydrogenation if transferred to hydrogen-rich environments.